Literature DB >> 30289007

Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.

Shyam Sundar1, Om Prakash Singh1, Jaya Chakravarty1.   

Abstract

INTRODUCTION: Visceral leishmaniasis (VL) is a fatal parasitic disease caused by a parasite belonging to the Leishmania donovani complex and transmitted by infected female Phlebotomous argentipes sand flies. The VL elimination strategy in the Indian subcontinent (ISC), which has a current goal of reducing the incidence of VL to below 1/10,000 of population by the year 2020, consists of rapid detection and treatment of VL to reduce the number of human reservoirs as well as vector control using indoor residual spraying (IRS). However, as the incidence of VL declines toward the elimination goal, greater targeting of control methods will be required to ensure appropriate early action to prevent the resurgence of VL. Area covered: We discuss the current progress and challenges in the VL elimination program and strategies to be employed to ensure sustained elimination of VL. Expert commentary: The VL elimination initiative has saved many human lives; however, for VL elimination to become a reality in a sustained way, an intense effort is needed, as substantial numbers of endemic subdistricts (primary health centers (PHCs) blocks level) are yet to reach the elimination target. In addition to effective epidemiological surveillance, appropriate diagnostic and treatment services for VL at PHCs will be needed to ensure long-term sustainability and prevent reemergence of VL.

Entities:  

Keywords:  Visceral leishmaniasis; elimination; resurgence; surveillance

Mesh:

Substances:

Year:  2018        PMID: 30289007      PMCID: PMC6345646          DOI: 10.1080/14787210.2018.1532790

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  47 in total

Review 1.  Leishmaniasis in the World Health Organization Eastern Mediterranean Region.

Authors:  Jose A Ruiz Postigo
Journal:  Int J Antimicrob Agents       Date:  2010-08-21       Impact factor: 5.283

2.  Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Authors:  Om Prakash Singh; Kamlesh Gidwani; Rajiv Kumar; Susanne Nylén; Stephen L Jones; Marleen Boelaert; David Sacks; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

3.  Visceral leishmaniasis and HIV coinfection in Bihar, India: a wake-up call?

Authors:  Johan van Griensven
Journal:  Clin Infect Dis       Date:  2014-05-10       Impact factor: 9.079

4.  A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis.

Authors:  Jaya Chakravarty; Subodh Kumar; Sonali Trivedi; Vijay K Rai; Anup Singh; Jill A Ashman; Elsa M Laughlin; Rhea N Coler; Stuart J Kahn; Anna Marie Beckmann; Karen D Cowgill; Steven G Reed; Shyam Sundar; Franco M Piazza
Journal:  Vaccine       Date:  2011-03-15       Impact factor: 3.641

5.  HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination.

Authors:  Sakib Burza; Raman Mahajan; Marta Gonzalez Sanz; Temmy Sunyoto; Ranjeet Kumar; Gaurab Mitra; María Angeles Lima
Journal:  Clin Infect Dis       Date:  2014-05-10       Impact factor: 9.079

Review 6.  Elimination of visceral leishmaniasis on the Indian subcontinent.

Authors:  Om Prakash Singh; Epco Hasker; Marleen Boelaert; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2016-09-28       Impact factor: 25.071

7.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

8.  Elimination of visceral leishmaniasis in the Indian subcontinent: a comparison of predictions from three transmission models.

Authors:  Epke A Le Rutte; Lloyd A C Chapman; Luc E Coffeng; Sarah Jervis; Epco C Hasker; Shweta Dwivedi; Morchan Karthick; Aritra Das; Tanmay Mahapatra; Indrajit Chaudhuri; Marleen C Boelaert; Graham F Medley; Sridhar Srikantiah; T Deirdre Hollingsworth; Sake J de Vlas
Journal:  Epidemics       Date:  2017-03       Impact factor: 4.396

9.  Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).

Authors:  Sakib Burza; Raman Mahajan; Prabhat K Sinha; Johan van Griensven; Krishna Pandey; María Angeles Lima; Marta Gonzalez Sanz; Temmy Sunyoto; Sunil Kumar; Gaurab Mitra; Ranjeet Kumar; Neena Verma; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-08-07

Review 10.  Implication of vector characteristics of Phlebotomus argentipes in the kala-azar elimination programme in the Indian sub-continent.

Authors:  Rajib Chowdhury; Vijay Kumar; Dinesh Mondal; Murari Lal Das; Pradeep Das; Aditya Prasad Dash; Axel Kroeger
Journal:  Pathog Glob Health       Date:  2016-05       Impact factor: 2.894

View more
  18 in total

1.  Discovery of 2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one derivatives as possible antileishmanial agents.

Authors:  Anuradha Seth; Anirban Ghoshal; Varun Dewaker; Ankita Rani; Sangh Priya Singh; Mukul Dutta; Shivani Katiyar; Sandeep Kumar Singh; Mamunur Rashid; Muhammad Wahajuddin; Susanta Kar; Ajay Kumar Srivastava
Journal:  RSC Med Chem       Date:  2022-05-11

Review 2.  Leishmaniasis: where are we and where are we heading?

Authors:  Santanu Sasidharan; Prakash Saudagar
Journal:  Parasitol Res       Date:  2021-04-07       Impact factor: 2.289

3.  The potential impact of human visceral leishmaniasis vaccines on population incidence.

Authors:  Epke A Le Rutte; Luc E Coffeng; Stefano Malvolti; Paul M Kaye; Sake J de Vlas
Journal:  PLoS Negl Trop Dis       Date:  2020-07-02

4.  Impact of Changes in Detection Effort on Control of Visceral Leishmaniasis in the Indian Subcontinent.

Authors:  Luc E Coffeng; Epke A Le Rutte; Johanna Muñoz; Emily R Adams; Joaquin M Prada; Sake J de Vlas; Graham F Medley
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

5.  Kala-azar elimination in a highly-endemic district of Bihar, India: A success story.

Authors:  Vijay Kumar; Rakesh Mandal; Sushmita Das; Shreekant Kesari; Diwakar Singh Dinesh; Krishna Pandey; Vidyanand Rabi Das; Roshan Kamal Topno; Madan Prasad Sharma; Rudra Kumar Dasgupta; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2020-05-04

6.  Structure and Antiparasitic Activity Relationship of Alkylphosphocholine Analogues against Leishmania donovani.

Authors:  Humera Ahmed; Katharine C Carter; Roderick A M Williams
Journal:  Microorganisms       Date:  2020-07-24

7.  Antileishmanial Activity and Synergistic Effects of Amphotericin B Deoxycholate with Allicin and Andrographolide against Leishmania martiniquensis In Vitro.

Authors:  Nuchpicha Intakhan; Wetpisit Chanmol; Pradya Somboon; Michelle D Bates; Vanessa Yardley; Paul A Bates; Narissara Jariyapan
Journal:  Pathogens       Date:  2020-01-09

8.  Costs and outcomes of active and passive case detection for visceral leishmaniasis (Kala-Azar) to inform elimination strategies in Bihar, India.

Authors:  Natalie J Dial; Graham F Medley; Simon L Croft; Tanmay Mahapatra; Khushbu Priyamvada; Bikas Sinha; Lucy Palmer; Fern Terris-Prestholt
Journal:  PLoS Negl Trop Dis       Date:  2021-02-03

9.  Immune Responses in Post Kala-azar Dermal Leishmaniasis.

Authors:  Mitali Chatterjee; Ritika Sengupta; Debanjan Mukhopadhyay; Shibabrata Mukherjee; Aishwarya Dighal; Srija Moulik; Shilpa Sengupta
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

10.  Development and Clinical Evaluation of Serum and Urine-Based Lateral Flow Tests for Diagnosis of Human Visceral Leishmaniasis.

Authors:  Sarfaraz Ahmad Ejazi; Somsubhra Thakur Choudhury; Anirban Bhattacharyya; Mohd Kamran; Krishna Pandey; Vidya Nand Ravi Das; Pradeep Das; Fernando Oliveira da Silva; Dorcas Lamounier Costa; Carlos Henrique Nery Costa; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  Microorganisms       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.